OBJECTIVE: To determine incidence of increased levels of alanine transferase (ALT) >2× upper limit of normal (ULN) in patients receivingmethotrexate (MTX), treated according to a dynamic strategy, and to identify predictors of ALT of >2× ULN. METHODS: Data of 508 recent-onset rheumatoid arthritis (RA) patients from the BeSt study, randomized to initial monotherapy or combination therapy, were used. Treatment was dynamic, aiming at a disease activity score = ≤ 2.4. ALT was measured every three months. With logistic regression analyses, baseline variables predictive of first ALT of >2× ULN were identified and the association between use of concomitant antirheumatic drugs, the actual and cumulative dose of MTX and ALT of >2× ULN was determined. RESULTS: In total, 498 patients ever initiated MTX, with a total duration on MTX of 1,416 patient-years. In 89 patients, a first incidence of ALT of >2× ULN occurred. Incidence rate was 6.3 per 100 patient-years and cumulative incidence 18 %. ACPA positivity and baseline ALT of >1× ULN were independent predictors of later ALT of >2× ULN (OR 1.8 (95 % CI, 1.1-3.1) and OR 3.1 (95 % CI, 1.6-6.2), respectively). Smoking showed a trend (OR 1.6 (95 % CI, 0.98-2.7)). Mean MTX dosage over time was higher in patients with an ALT of >2× ULN. Patients who did not have an ALT of >2×ULN used more concomitant disease-modifying antirheumatic drugs and longer. CONCLUSIONS: In RA patients treated with MTX according to a dynamic strategy resembling daily clinical practice, incidence of increased ALT of >2× ULN was lower than previously reported, and also without treatment adjustments, persistence was rare. The recommendations for ALT monitoring may be reevaluated.
RCT Entities:
OBJECTIVE: To determine incidence of increased levels of alanine transferase (ALT) >2× upper limit of normal (ULN) in patients receiving methotrexate (MTX), treated according to a dynamic strategy, and to identify predictors of ALT of >2× ULN. METHODS: Data of 508 recent-onset rheumatoid arthritis (RA) patients from the BeSt study, randomized to initial monotherapy or combination therapy, were used. Treatment was dynamic, aiming at a disease activity score = ≤ 2.4. ALT was measured every three months. With logistic regression analyses, baseline variables predictive of first ALT of >2× ULN were identified and the association between use of concomitant antirheumatic drugs, the actual and cumulative dose of MTX and ALT of >2× ULN was determined. RESULTS: In total, 498 patients ever initiated MTX, with a total duration on MTX of 1,416 patient-years. In 89 patients, a first incidence of ALT of >2× ULN occurred. Incidence rate was 6.3 per 100 patient-years and cumulative incidence 18 %. ACPA positivity and baseline ALT of >1× ULN were independent predictors of later ALT of >2× ULN (OR 1.8 (95 % CI, 1.1-3.1) and OR 3.1 (95 % CI, 1.6-6.2), respectively). Smoking showed a trend (OR 1.6 (95 % CI, 0.98-2.7)). Mean MTX dosage over time was higher in patients with an ALT of >2× ULN. Patients who did not have an ALT of >2× ULN used more concomitant disease-modifying antirheumatic drugs and longer. CONCLUSIONS: In RApatients treated with MTX according to a dynamic strategy resembling daily clinical practice, incidence of increased ALT of >2× ULN was lower than previously reported, and also without treatment adjustments, persistence was rare. The recommendations for ALT monitoring may be reevaluated.
Authors: A A Drosos; D Psychos; A P Andonopoulos; S Stefanaki-Nikou; E B Tsianos; H M Moutsopoulos Journal: Clin Rheumatol Date: 1990-09 Impact factor: 2.980
Authors: F Pessione; M J Ramond; C Njapoum; V Duchatelle; C Degott; S Erlinger; B Rueff; D C Valla; F Degos Journal: Hepatology Date: 2001-07 Impact factor: 17.425
Authors: Jeremy Sokolove; Vibeke Strand; Jeffrey D Greenberg; Jeffrey R Curtis; Arthur Kavanaugh; Joel M Kremer; Alina Anofrei; George Reed; Leonard Calabrese; Michele Hooper; Scott Baumgartner; Daniel E Furst Journal: Ann Rheum Dis Date: 2010-05-06 Impact factor: 19.103
Authors: Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans Journal: Arthritis Rheum Date: 2005-11
Authors: S M van der Kooij; Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; M Güler-Yüksel; A H Zwinderman; P J S M Kerstens; P A H M van der Lubbe; W M de Beus; B A M Grillet; H K Ronday; T W J Huizinga; F C Breedveld; B A C Dijkmans; C F Allaart Journal: Ann Rheum Dis Date: 2008-07-28 Impact factor: 19.103
Authors: J R Curtis; T Beukelman; A Onofrei; S Cassell; J D Greenberg; A Kavanaugh; G Reed; V Strand; J M Kremer Journal: Ann Rheum Dis Date: 2010-01 Impact factor: 19.103
Authors: S E Lester; S M Proudman; A T Y Lee; C A Hall; L McWilliams; M J James; L G Cleland Journal: Intern Med J Date: 2008-06-28 Impact factor: 2.048
Authors: Georgina Nakafero; Matthew J Grainge; Tim Card; Maarten W Taal; Guruprasad P Aithal; Weiya Zhang; Michael Doherty; Christopher P Fox; Christian D Mallen; Abhishek Abhishek Journal: Rheumatology (Oxford) Date: 2022-07-06 Impact factor: 7.046
Authors: Ahmad A Sherbini; James M Gwinnutt; Kimme L Hyrich; Suzanne M M Verstappen Journal: Rheumatology (Oxford) Date: 2022-10-06 Impact factor: 7.046
Authors: Georgina Nakafero; Matthew J Grainge; Tim Card; Christian D Mallen; Weiya Zhang; Michael Doherty; Maarten W Taal; Guruprasad P Aithal; Abhishek Abhishek Journal: Rheumatology (Oxford) Date: 2021-12-01 Impact factor: 7.580